Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The benefits of intravenous tissue plasminogen activator (tPA) in patients with acute ischemic stroke (AIS) are time dependent and guidelines recommend a door-to-needle (DTN) time of 60 minutes or less. However, studies have found that less than 30% of US patients are treated within this time window.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JAMA

Title: JAMA

Publisher: American Medical Association (AMA)

ISSN (Electronic): 1538-3598

ISSN (Print): 0098-7484

Publication date (Electronic): April 24 2014

Volume: 311

Issue: 16

Affiliations

[1 ] Division of Cardiology, University of California, Los Angeles.

[2 ] Duke Clinical Research Center, Durham, North Carolina.

[3 ] Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.

[4 ] Department of Neurology, University of California, Los Angeles.

[5 ] Department of Epidemiology, Michigan State University, East Lansing.

[6 ] Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts.

[7 ] Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.

Article

Publisher Item ID: 1861802

DOI: 10.1001/jama.2014.3203

PubMed ID: 24756513

SO-VID: ca695f1c-4102-4c16-a54d-133680ab18e3

History

Data availability:

Comments

Comment on this article

scite_

Cited by 169

See all cited by

- Version 1
- Version 1